高密度脂蛋白胆固醇水平与血液恶性肿瘤风险的关联
基于韩国国民健康保险服务2009-2017年数据,对9,596,145名≥20岁人群进行竞争风险回归分析,平均随访8.3年(79,179,225人年)发现15,864例新发血液恶性肿瘤。与最高HDL-C四分位组相比,最低HDL-C四分位组全部血液肿瘤合计风险及MM、HL、NHL、LL、ML各型风险均显著升高。
要点
- 低HDL-C水平与血液恶性肿瘤风险升高独立相关。
- MM风险升高最显著(HR 1.61, 95%CI 1.46-1.76)。
- 低HDL-C或可作为血液恶性肿瘤的临床前标志物。
核心结论
- 低HDL-C水平显著关联血液恶性肿瘤风险增加,提示其可能是独立危险因素和临床前标志物。
研究设计与样本
- 基于韩国国民健康保险服务2009-2017年数据的回顾性队列研究,纳入9,596,145名≥20岁个体,采用竞争风险回归分析。
主要发现
- 平均随访8.3年(79,179,225人年)期间共识别15,864例新发血液恶性肿瘤。
- 与最高HDL-C四分位组相比,最低HDL-C四分位组全部血液肿瘤合计风险升高( adjusted HR 1.31, 95%CI 1.25-1.37)。
- MM风险HR 1.61(95%CI 1.46-1.76),HL风险HR 1.35(95%CI 1.07-1.70),NHL风险HR 1.12(95%CI 1.04-1.21),LL风险HR 1.36(95%CI 1.16-1.61),ML风险HR 1.33(95%CI 1.22-1.45)。
临床怎么用
- 在临床评估中,低HDL-C水平或可提示血液恶性肿瘤风险升高,需结合其他指标综合判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study investigated the relationships between HDL-C and major types of blood cancers. Competing risks regression was used to examine the hazard ratios of hematologic malignancies in 9,596,145 individuals (≥20 years) using data from the Korean National Health Insurance Service (2009-2017). The incidence of the following hematologic cancers was determined based on the International Classification of Diseases 10th revision: Multiple Myeloma (MM), Hodgkin Lymphoma (HL), Non-Hodgkin Lymphoma (NHL), Lymphoid Leukemia (LL), and Myeloid Leukemia (ML). During an average of 8.3 years of follow-up (79,179,225 person-years), 15,864 incident hematologic malignancies were identified. Compared to those in the highest HDL-C quartile, subjects in the lowest HDL-C quartile had the highest risk of all hematologic cancers combined (adjusted hazard ratio [HR], 95% confidence interval [95% CI] = 1.31, 1.25-1.37) and of each respective type of blood cancer, as follows: MM (HR 1.61, 95% CI, 1.46-1.76), HL (HR 1.35, 95% CI 1.07-1.70), NHL (HR 1.12, 95%CI 1.04-1.21), LL (HR 1.36, 95% CI 1.16-1.61), and ML (HR 1.33, 95% CI 1.22-1.45). Low HDL-C level was significantly associated with increased risk of hematologic malignancy, suggesting that a low HDL-C level is an independent risk factor and preclinical marker for hematologic malignancy.
引用
- Jeong SM, Choi T, Kim D, et al. Association between high-density lipoprotein cholesterol level and risk of hematologic malignancy. Leukemia. 2020. PMID: 33268820. doi:10.1038/s41375-020-01081-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。